[ 3H]-8-OH-DPAT binding in the rat brain raphe area: Involvement of 5-HT(1A) and non-5-HT(1A) receptors

Marie Bernadette Assié, Wouter Koek

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

1. The 5-HT(1A) agonist 8-OH-DPAT has been shown to have additional 5-HT uptake inhibiting properties. The present work was undertaken to examine further the binding of [ 3H]-8-OH-DPAT in the raphe area of the rat brain, a region rich in 5-HT(1A) receptors and 5-HT uptake sites. 2. 5-HT inhibited [ 3H]-8-OH-DPAT binding in a biphasic manner (pK(i1): 8.82 ± 0.01, pK(i2): 6.07 ± 0.05, n = 4) with the low affinity site representing 36 ± 4% of the total population. A biphasic inhibition curve was found also with the 5-HT(1A) antagonist, WAY 100635 (pK(i1): 8.65 ± 0.17, pK(i2): 4.26 ± 0.38, n = 3). In the presence of 1 μM WAY 100635 to mask 5-HT(1A) receptors, 5-HT inhibited [ 3H]-8-OH-DPAT binding in a monophasic manner (pK(i): 6.04 ± 0.07, n = 3). 3. The affinities of various compounds for sites labelled by [ 3H]-8-OH-DPAT in the presence of 1 μM WAY 100635 and for sites labelled by [ 3H]-citalopram (a selective 5-HT uptake inhibitor) were determined. There was a significant correlation between pK(i) values at 5-HT uptake sites and at non-5HT(1A) sites labelled by [ 3H]-8-OH-DPAT (r = 0.80, P < 0.001, n = 17), suggesting these latter sites to be 5-HT uptake sites. 4. Whereas the affinities of RC(+) and S(-) enantiomers of 8-OH-DPAT for the 5-HT uptake site are similar, R(+)8-OH-DPAT has 10 times higher affinity for the non-5-HT(1A) site than S(-)8-OH-DPAT and was considered as an outlier in the correlation. It is suggested that [ 3H]-8-OH-DPAT labels other, as yet unknown binding sites in the raphe.

Original languageEnglish (US)
Pages (from-to)1348-1352
Number of pages5
JournalBritish Journal of Pharmacology
Volume130
Issue number6
StatePublished - 2000
Externally publishedYes

Fingerprint

8-Hydroxy-2-(di-n-propylamino)tetralin
Serotonin
Brain
Receptor, Serotonin, 5-HT1A
hydroxide ion
Serotonin Receptor Agonists
Citalopram
Serotonin Antagonists
Serotonin Uptake Inhibitors
Masks
Binding Sites

Keywords

  • 5-HT
  • 5-HT uptake
  • 5-HT(1A) receptors
  • 8-OH-DPAT
  • [ H]-8-OH-DPAT binding
  • Raphe

ASJC Scopus subject areas

  • Pharmacology

Cite this

[ 3H]-8-OH-DPAT binding in the rat brain raphe area : Involvement of 5-HT(1A) and non-5-HT(1A) receptors. / Assié, Marie Bernadette; Koek, Wouter.

In: British Journal of Pharmacology, Vol. 130, No. 6, 2000, p. 1348-1352.

Research output: Contribution to journalArticle

@article{b2008d32300c465380dfe2d304ae3168,
title = "[ 3H]-8-OH-DPAT binding in the rat brain raphe area: Involvement of 5-HT(1A) and non-5-HT(1A) receptors",
abstract = "1. The 5-HT(1A) agonist 8-OH-DPAT has been shown to have additional 5-HT uptake inhibiting properties. The present work was undertaken to examine further the binding of [ 3H]-8-OH-DPAT in the raphe area of the rat brain, a region rich in 5-HT(1A) receptors and 5-HT uptake sites. 2. 5-HT inhibited [ 3H]-8-OH-DPAT binding in a biphasic manner (pK(i1): 8.82 ± 0.01, pK(i2): 6.07 ± 0.05, n = 4) with the low affinity site representing 36 ± 4{\%} of the total population. A biphasic inhibition curve was found also with the 5-HT(1A) antagonist, WAY 100635 (pK(i1): 8.65 ± 0.17, pK(i2): 4.26 ± 0.38, n = 3). In the presence of 1 μM WAY 100635 to mask 5-HT(1A) receptors, 5-HT inhibited [ 3H]-8-OH-DPAT binding in a monophasic manner (pK(i): 6.04 ± 0.07, n = 3). 3. The affinities of various compounds for sites labelled by [ 3H]-8-OH-DPAT in the presence of 1 μM WAY 100635 and for sites labelled by [ 3H]-citalopram (a selective 5-HT uptake inhibitor) were determined. There was a significant correlation between pK(i) values at 5-HT uptake sites and at non-5HT(1A) sites labelled by [ 3H]-8-OH-DPAT (r = 0.80, P < 0.001, n = 17), suggesting these latter sites to be 5-HT uptake sites. 4. Whereas the affinities of RC(+) and S(-) enantiomers of 8-OH-DPAT for the 5-HT uptake site are similar, R(+)8-OH-DPAT has 10 times higher affinity for the non-5-HT(1A) site than S(-)8-OH-DPAT and was considered as an outlier in the correlation. It is suggested that [ 3H]-8-OH-DPAT labels other, as yet unknown binding sites in the raphe.",
keywords = "5-HT, 5-HT uptake, 5-HT(1A) receptors, 8-OH-DPAT, [ H]-8-OH-DPAT binding, Raphe",
author = "Assi{\'e}, {Marie Bernadette} and Wouter Koek",
year = "2000",
language = "English (US)",
volume = "130",
pages = "1348--1352",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - [ 3H]-8-OH-DPAT binding in the rat brain raphe area

T2 - Involvement of 5-HT(1A) and non-5-HT(1A) receptors

AU - Assié, Marie Bernadette

AU - Koek, Wouter

PY - 2000

Y1 - 2000

N2 - 1. The 5-HT(1A) agonist 8-OH-DPAT has been shown to have additional 5-HT uptake inhibiting properties. The present work was undertaken to examine further the binding of [ 3H]-8-OH-DPAT in the raphe area of the rat brain, a region rich in 5-HT(1A) receptors and 5-HT uptake sites. 2. 5-HT inhibited [ 3H]-8-OH-DPAT binding in a biphasic manner (pK(i1): 8.82 ± 0.01, pK(i2): 6.07 ± 0.05, n = 4) with the low affinity site representing 36 ± 4% of the total population. A biphasic inhibition curve was found also with the 5-HT(1A) antagonist, WAY 100635 (pK(i1): 8.65 ± 0.17, pK(i2): 4.26 ± 0.38, n = 3). In the presence of 1 μM WAY 100635 to mask 5-HT(1A) receptors, 5-HT inhibited [ 3H]-8-OH-DPAT binding in a monophasic manner (pK(i): 6.04 ± 0.07, n = 3). 3. The affinities of various compounds for sites labelled by [ 3H]-8-OH-DPAT in the presence of 1 μM WAY 100635 and for sites labelled by [ 3H]-citalopram (a selective 5-HT uptake inhibitor) were determined. There was a significant correlation between pK(i) values at 5-HT uptake sites and at non-5HT(1A) sites labelled by [ 3H]-8-OH-DPAT (r = 0.80, P < 0.001, n = 17), suggesting these latter sites to be 5-HT uptake sites. 4. Whereas the affinities of RC(+) and S(-) enantiomers of 8-OH-DPAT for the 5-HT uptake site are similar, R(+)8-OH-DPAT has 10 times higher affinity for the non-5-HT(1A) site than S(-)8-OH-DPAT and was considered as an outlier in the correlation. It is suggested that [ 3H]-8-OH-DPAT labels other, as yet unknown binding sites in the raphe.

AB - 1. The 5-HT(1A) agonist 8-OH-DPAT has been shown to have additional 5-HT uptake inhibiting properties. The present work was undertaken to examine further the binding of [ 3H]-8-OH-DPAT in the raphe area of the rat brain, a region rich in 5-HT(1A) receptors and 5-HT uptake sites. 2. 5-HT inhibited [ 3H]-8-OH-DPAT binding in a biphasic manner (pK(i1): 8.82 ± 0.01, pK(i2): 6.07 ± 0.05, n = 4) with the low affinity site representing 36 ± 4% of the total population. A biphasic inhibition curve was found also with the 5-HT(1A) antagonist, WAY 100635 (pK(i1): 8.65 ± 0.17, pK(i2): 4.26 ± 0.38, n = 3). In the presence of 1 μM WAY 100635 to mask 5-HT(1A) receptors, 5-HT inhibited [ 3H]-8-OH-DPAT binding in a monophasic manner (pK(i): 6.04 ± 0.07, n = 3). 3. The affinities of various compounds for sites labelled by [ 3H]-8-OH-DPAT in the presence of 1 μM WAY 100635 and for sites labelled by [ 3H]-citalopram (a selective 5-HT uptake inhibitor) were determined. There was a significant correlation between pK(i) values at 5-HT uptake sites and at non-5HT(1A) sites labelled by [ 3H]-8-OH-DPAT (r = 0.80, P < 0.001, n = 17), suggesting these latter sites to be 5-HT uptake sites. 4. Whereas the affinities of RC(+) and S(-) enantiomers of 8-OH-DPAT for the 5-HT uptake site are similar, R(+)8-OH-DPAT has 10 times higher affinity for the non-5-HT(1A) site than S(-)8-OH-DPAT and was considered as an outlier in the correlation. It is suggested that [ 3H]-8-OH-DPAT labels other, as yet unknown binding sites in the raphe.

KW - 5-HT

KW - 5-HT uptake

KW - 5-HT(1A) receptors

KW - 8-OH-DPAT

KW - [ H]-8-OH-DPAT binding

KW - Raphe

UR - http://www.scopus.com/inward/record.url?scp=0033943451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033943451&partnerID=8YFLogxK

M3 - Article

C2 - 10903975

AN - SCOPUS:0033943451

VL - 130

SP - 1348

EP - 1352

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 6

ER -